10x Genomics, Inc.

NasdaqGS:TXG Stock Report

Market Cap: US$2.8b

10x Genomics Valuation

Is TXG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of TXG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: TXG ($20.81) is trading below our estimate of future cash flow value ($32.68)

Significantly Below Future Cash Flow Value: TXG is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TXG?

Key metric: As TXG is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TXG. This is calculated by dividing TXG's market cap by their current revenue.
What is TXG's PS Ratio?
PS Ratio4.1x
SalesUS$642.82m
Market CapUS$2.76b

Price to Sales Ratio vs Peers

How does TXG's PS Ratio compare to its peers?

The above table shows the PS ratio for TXG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.1x
ADPT Adaptive Biotechnologies
8.3x14.64%US$2.3b
SHC Sotera Health
3.6x5.89%US$4.2b
STVN Stevanato Group
3.1x7.96%US$4.3b
BRKR Bruker
1.6x4.34%US$5.9b
TXG 10x Genomics
4.1x5.27%US$2.8b

Price-To-Sales vs Peers: TXG is expensive based on its Price-To-Sales Ratio (4.1x) compared to the peer average (4.1x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does TXG's PS Ratio compare vs other companies in the US Life Sciences Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.3x2.52%US$927.52m
ATLN Atlantic International
0.5x7.04%US$225.38m
SNCE Science 37 Holdings
0.6x17.47%US$34.67m
HBIO Harvard Bioscience
0.3x5.14%US$25.54m
TXG 4.1xIndustry Avg. 2.8xNo. of Companies10PS02.44.87.29.612+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TXG is expensive based on its Price-To-Sales Ratio (4.1x) compared to the US Life Sciences industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is TXG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TXG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.1x
Fair PS Ratio4x

Price-To-Sales vs Fair Ratio: TXG is expensive based on its Price-To-Sales Ratio (4.1x) compared to the estimated Fair Price-To-Sales Ratio (4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TXG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$20.81
US$20.14
-3.21%
10.08%US$25.00US$17.00n/a14
Mar ’27US$23.05
US$19.79
-14.16%
7.68%US$22.00US$17.00n/a14
Feb ’27US$20.20
US$18.08
-10.51%
13.46%US$22.00US$14.00n/a13
Jan ’27US$16.31
US$17.36
+6.42%
13.53%US$22.00US$14.00n/a14
Dec ’26US$18.08
US$16.36
-9.53%
10.99%US$19.00US$14.00n/a14
Nov ’26US$13.64
US$14.86
+8.92%
8.38%US$17.00US$13.00n/a14
Oct ’26US$12.39
US$15.07
+21.64%
7.72%US$17.00US$13.00n/a14
Sep ’26US$14.01
US$15.08
+7.62%
8.00%US$17.00US$13.00n/a13
Aug ’26US$13.08
US$13.54
+3.51%
17.29%US$18.00US$9.00n/a13
Jul ’26US$12.06
US$13.08
+8.43%
18.36%US$18.00US$9.00n/a13
Jun ’26US$9.53
US$12.46
+30.79%
23.02%US$18.00US$6.50n/a14
May ’26US$8.10
US$15.27
+88.51%
28.16%US$26.00US$7.50n/a13
Apr ’26US$8.67
US$16.31
+88.09%
21.16%US$26.00US$12.00n/a13
Mar ’26US$10.69
US$16.36
+53.01%
22.24%US$26.00US$12.00US$23.0514
Feb ’26US$15.00
US$20.14
+34.29%
18.84%US$28.00US$14.00US$20.2014
Jan ’26US$14.36
US$20.29
+41.27%
20.28%US$30.00US$14.00US$16.3114
Dec ’25US$15.90
US$20.29
+27.58%
20.28%US$30.00US$14.00US$18.0814
Nov ’25US$16.33
US$20.29
+24.22%
20.28%US$30.00US$14.00US$13.6414
Oct ’25US$21.31
US$26.77
+25.61%
27.81%US$46.00US$16.00US$12.3915
Sep ’25US$23.35
US$26.69
+14.31%
27.70%US$46.00US$16.00US$14.0113
Aug ’25US$19.68
US$28.54
+45.01%
35.30%US$50.00US$16.00US$13.0813
Jul ’25US$18.59
US$39.62
+113.10%
28.05%US$55.00US$24.00US$12.0613
Jun ’25US$22.42
US$41.14
+83.51%
22.10%US$55.00US$26.00US$9.5314
May ’25US$26.92
US$40.38
+49.99%
22.75%US$55.00US$26.00US$8.1014
Apr ’25US$37.05
US$57.79
+55.97%
15.67%US$70.00US$30.00US$8.6714
Mar ’25US$45.56
US$57.79
+26.83%
15.67%US$70.00US$30.00US$10.6914
US$20.14
Fair Value
3.3% overvalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/06 02:19
End of Day Share Price 2026/03/06 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

10x Genomics, Inc. is covered by 22 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Michael RyskinBofA Global Research
Kyle MiksonCanaccord Genuity